Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide guidelines for dosing and are often extrapolated for APD use, but it is unclear whether this is appropriate. This review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically summarized, knowledge gaps explored, and a vancomycin dosing algorithm in PD patients is proposed.
Recommended CitationLam, Edwin; Lien, Yi Ting Kayla; Kraft, Walter K.; Piraino, Beth; Vozmediano, Valvanera; Schmidt, Stephan; and Zhang, Jingjing, "Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy." (2020). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 118.